Business Context and Reporting Period
This Form 8-K, filed on January 24, 2001, reports on Bristol-Myers Squibb Company's financial position as of December 31, 1999. The filing primarily addresses the restatement of historical financial data following the September 28, 2000, announcement of the planned divestitures of the Clairol (Beauty Care) and Zimmer (Medical Devices) businesses. Consequently, these segments are now classified as discontinued operations. The company is refocusing its operations on its Medicines segment.
Key Financial Metrics (Year Ended December 31, 1999)
| Metric | 1999 (Restated) | 1998 (Restated) |
|---|---|---|
| Net Sales | $16,878 million | $15,061 million |
| Net Earnings | $4,167 million | $3,141 million |
| Earnings from Continuing Operations | $3,789 million | $2,750 million |
| Net Earnings from Discontinued Operations | $378 million | $391 million |
| Diluted EPS (Net Earnings) | $2.06 | $1.55 |
| Operating Cash Flow | $4,470 million | $4,120 million |
| Total Assets | $17,114 million | $16,272 million |
| Long-Term Debt | $1,342 million | $1,364 million |
| Cash and Cash Equivalents | $2,720 million | $2,244 million |
Material Changes and Restatements
- Discontinued Operations: The most significant change is the reclassification of Clairol and Zimmer as discontinued operations. In 1999, these businesses contributed $3,344 million in net sales and $378 million in net earnings.
- Revenue Growth: Consolidated net sales increased 12.1% to $16.878 billion in 1999 compared to 1998, driven by growth in the Medicines segment (e.g., Pravachol, Taxol, Glucophage).
- Profitability: Net earnings from continuing operations rose 37.8% to $3.789 billion, excluding the impact of discontinued operations.
- Special Charges: The 1998 results included a significant $800 million pre-tax special charge related to breast implant and prescription drug pricing litigation, which is not present in the 1999 results.
Outlook, Risks, and Contingencies
- Divestitures: The company expects to complete the divestiture of Clairol and Zimmer in 2001. The net assets of these discontinued operations were $1,195 million as of December 31, 1999.
- Litigation Risks:
- Breast Implants: Approximately 950 opt-out plaintiffs remain. The company has a reserve of $354 million (current and other liabilities) and believes it can address remaining obligations within existing reserves.
- TAXOL* Patents: A district court ruled most of the company's patents invalid, except for claims limited to ovarian cancer treatment. The company has appealed this decision. Generic competitors received FDA approval to market paclitaxel for breast cancer in September 2000.
- Prescription Drug Pricing: The company remains a defendant in antitrust and pricing actions but maintains a $100 million reserve established in 1998.
- Vanlev Litigation: Securities class actions are pending regarding safety and availability disclosures; no material adverse effect is currently anticipated.
- Stock-Based Compensation: If calculated under FAS 123 (fair value method), 1999 net income would have been reduced by approximately $198 million ($0.10 per share).
Investor Verification Checklist
- Verify the timeline and expected proceeds for the divestiture of Clairol and Zimmer businesses.
- Monitor the status of the TAXOL* patent appeal and the potential impact of generic competition on oncology sales.
- Review the adequacy of the $354 million reserve for breast implant liabilities against the remaining 950 opt-out claims.
- Assess the impact of the 1998 special charges on year-over-year comparisons of continuing operations profitability.
- Confirm the company's ability to maintain liquidity given the $1.4 billion in treasury stock purchases in 1999.